# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
JP Morgan analyst Eric Joseph maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...
Oppenheimer analyst Matthew Biegler maintains Relay Therapeutics (NASDAQ:RLAY) with a Outperform and lowers the price target...
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.69) per share which beat the analyst consensus estimate of $(...
Barclays analyst Peter Lawson maintains Relay Therapeutics (NASDAQ:RLAY) with a Overweight and lowers the price target from ...
JMP Securities analyst Silvan Tuerkcan maintains Relay Therapeutics (NASDAQ:RLAY) with a Market Outperform and lowers the pr...
HC Wainwright & Co. analyst Robert Burns maintains Relay Therapeutics (NASDAQ:RLAY) with a Buy and lowers the price targ...
Effective In 180 Days; Agreement Involved Development Of Migoprotafib (GDC-1971); No Further Payments Or Obligations After Term...